Volume 16, Number 10—October 2010
Dispatch
Epidemiology of Human Parvovirus 4 Infection in Sub-Saharan Africa
Table
Seroprevalence of human parvovirus 4 antibodies in sub-Saharan African and control populations*
Country |
Category |
No. |
Co-infection | Mean year of birth (range) |
Collection year |
PARV4 positive,
no. (%) |
|
---|---|---|---|---|---|---|---|
HIV† |
HCV‡ |
||||||
Burkina Faso | Blood donors | 167 | 0 | 0 | 1982 (1951–1999) | 2007 | 62 (37.1) |
Cameroon | General population | 238 | 0 | 0 | 1968 (1962–1972) | 2007 | 59 (24.8) |
Democratic Republic of the Congo | Military population | 221 | 2§ | 0 | 1968 (1936–1986) | 2007 | 78 (35.3) |
South Africa | Blood donors (HIV-positive) | 170 | 170 | 0 | 1976 (1945–1990) | 2007 | 62 (36.4) |
South Africa | Blood donors (HIV-negative) | 180 | 0 | 0 | NA | 2009 | 8 (4.4) |
United Kingdom | General population | 161 | ND | ND | 1950 (1937–1977) | 2005 | 0 |
France | Blood donors | 199 | 0 | 0 | 1965 (1943–1989) | 2008 | 0 |
*HCV, hepatitis C virus; PARV4, human parvovirus 4; NA, not available; ND, screening not done.
†HIV-1 screening methods: South Africa, France: fourth-generation ELISA.
‡HCV screening methods: Burkina-Faso, South Africa, France: third-generation ELISA, recombinant immunoblot assay confirmation of positive results; Democratic Republic of the Congo: third-generation ELISA, exclusion of reactive samples; Cameroon: PCR-based screening, exclusion of PCR-positive samples. United Kingdom: not screened (ND), low risk background and absence of parenteral or HIV risk factors.
§1 of 2 HIV-positive samples was seropositive for PARV4.